Implementation and Yield of Upfront Genomic Profiling in a Clinical Prostate Cancer Diagnostic Pathway
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Kishan A, Chu F, King C, Seiferheld W, Spratt D, Tran P
. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol. 2019; 77(2):201-208.
PMC: 7008470.
DOI: 10.1016/j.eururo.2019.10.008.
View
2.
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N
. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018; 29(9):1895-1902.
PMC: 6158764.
DOI: 10.1093/annonc/mdy263.
View
3.
Barrett T, Slough R, Sushentsev N, Shaida N, Koo B, Caglic I
. Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways. Clin Radiol. 2019; 74(11):894.e1-894.e9.
DOI: 10.1016/j.crad.2019.06.004.
View
4.
Parry M, Cowling T, Sujenthiran A, Nossiter J, Berry B, Cathcart P
. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation. BMC Med. 2020; 18(1):114.
PMC: 7254634.
DOI: 10.1186/s12916-020-01588-9.
View
5.
Ku S, Gleave M, Beltran H
. Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 2019; 16(11):645-654.
PMC: 6858516.
DOI: 10.1038/s41585-019-0237-8.
View